Zofran (ondansetron), manufactured by GlaxoSmithKline, is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran was approved by the Food and Drug Administration (FDA) in January 1991, to treat chemotherapy-related nausea, and the approval was later expanded to treat postoperative nausea